Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

Baker Capital Strategies

Free Registration

Register for access to news, tools, alerts and reports.

THEMA Basic included at launch.

Use at least 8 characters.

Home/The Filing Wire/Revance Therapeutics, Inc./ 10-K

Annual Report · 10-K

Revance Therapeutics, Inc.

Annual Report

Filed Feb 28, 2022Accepted Feb 28, 2022, 11:35 AM ESTCIK 1479290Accession 0001479290-22-000034
View company →Permanent SEC source ↗
Share

Recent company filings

  1. SCHEDULE 13G/A - filed by Beryl Capital Management LLC regarding Revance Therapeutics, Inc.May 15, 2025
  2. SCHEDULE 13G/A - filed by JPMORGAN CHASE & CO regarding Revance Therapeutics, Inc.Mar 6, 2025
  3. 15-12G filingFeb 18, 2025
  4. SCHEDULE 13G/A - filed by Palo Alto Investors LP regarding Revance Therapeutics, Inc.Feb 13, 2025
  5. S-8 POS filingFeb 12, 2025

Document unavailable

This filing is not currently available in the archive. Read it on SEC EDGAR ↗